A detailed history of Ameriprise Financial Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 31,180 shares of NTLA stock, worth $445,874. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,180
Previous 35,971 13.32%
Holding current value
$445,874
Previous $805,000 20.5%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $94,478 - $131,081
-4,791 Reduced 13.32%
31,180 $640,000
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $77,097 - $104,824
3,851 Added 11.99%
35,971 $805,000
Q1 2024

May 15, 2024

SELL
$23.82 - $32.8 $6.6 Million - $9.09 Million
-277,092 Reduced 89.61%
32,120 $883,000
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $6.39 Million - $8.92 Million
275,857 Added 827.03%
309,212 $9.43 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $524,955 - $760,039
16,602 Added 99.1%
33,355 $1.05 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $9,198 - $12,243
266 Added 1.61%
16,753 $683,000
Q1 2023

May 15, 2023

SELL
$33.3 - $44.82 $13.1 Million - $17.7 Million
-394,335 Reduced 95.99%
16,487 $614,000
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $802,154 - $1.51 Million
-24,154 Reduced 5.55%
410,822 $14.3 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $1.12 Million - $1.49 Million
20,819 Added 5.03%
434,976 $24.3 Million
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $692,935 - $1.37 Million
-18,003 Reduced 4.17%
414,157 $21.4 Million
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $310,579 - $634,216
-5,330 Reduced 1.22%
432,160 $31.4 Million
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $71,841 - $98,650
713 Added 0.16%
437,490 $51.7 Million
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $29 Million - $38.8 Million
219,321 Added 100.86%
436,777 $58.6 Million
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $12.3 Million - $32.8 Million
202,813 Added 1385.05%
217,456 $35.2 Million
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $302,369 - $543,083
6,490 Added 79.6%
14,643 $1.22 Million
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $153,520 - $517,960
8,153 New
8,153 $312,000
Q4 2019

Feb 14, 2020

SELL
$10.43 - $17.67 $117,660 - $199,335
-11,281 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$13.07 - $18.51 $308,059 - $436,280
-23,570 Reduced 67.63%
11,281 $150,000
Q2 2019

Aug 14, 2019

BUY
$13.88 - $18.41 $320,031 - $424,479
23,057 Added 195.5%
34,851 $570,000
Q1 2019

May 15, 2019

BUY
$12.79 - $17.62 $150,845 - $207,810
11,794 New
11,794 $202,000
Q4 2018

Feb 14, 2019

SELL
$11.39 - $27.13 $1.07 Million - $2.56 Million
-94,381 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$25.78 - $32.6 $248,519 - $314,264
-9,640 Reduced 9.27%
94,381 $2.7 Million
Q2 2018

Aug 14, 2018

BUY
$20.02 - $30.79 $2.08 Million - $3.2 Million
104,021 New
104,021 $2.76 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.